Update on house dust mite immunotherapy: Are more studies needed?

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 6, 2014, Pages 542-548

  Nelson, Harold S ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy immunotherapy; Dermatophagoides farinae; Dermatophagoides pteronyssinus; House dust mite; Subcutaneous; Sublingual

Indexed keywords

HOUSE DUST ALLERGEN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; HOUSE DUST; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; ANIMAL; ASTHMA; CHILD; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PRESCHOOL CHILD; PROCEDURES; PYROGLYPHIDAE; RHINITIS, ALLERGIC; SUBLINGUAL IMMUNOTHERAPY;

ANIMALS; ASTHMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; PYROGLYPHIDAE; RHINITIS, ALLERGIC; SUBLINGUAL IMMUNOTHERAPY;

EID: 84927694902     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000104     Document Type: Review

References (14)

1. Erekosima N, Suarez-Cuervo C, Rammanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014; 124:616-627.
2. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013; 309:1278-1288.
3. Calderon MA, Casale TB, Nelson HS, et al. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013; 132:1322-1336.
4. Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014; 133:1608-1614.
5. Bozek A, Ignasiak B, Filiipowska B, et al. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy 2013; 43:242-248.
6. Horak F, Maloney J, Nelson HS, et al. Onset of action of house dust mite sublingual immunotherapy tablet (SLIT-T) using an environmental exposure chamber. Oral presentation AAAAI Annual Meeting; 28 February-3 March 2014; San Diego, California.
7. Nolte H, Maloney J, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet (SLIT-T) on ocular symptoms using an environmental exposure chamber. Presented 32nd Aspen Allergy Conference; 22-26 July 2014; Aspen, Colorado.
8. Wang DH, Chen L, Cheng L, et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope 2013; 123:1334-1340.
9. Queiros MGJ, Silva DAO, Siman IL, et al. Modulation of mucosal/systemic antibody response after sublingual immunotherapy in mite-allergic children. Ped Allergy Immunol 2013; 24:752-761.
10. Tian M, Wang Y, Lu Y, et al. Effects of sublingual immunotherapy for Dermatophagoides farinae on Th17 cells and CD4+CD25+ regulatory T cells in peripheral blood of children with allergic asthma. Int Forum Allergy Rhinol 2014; 4:371-375.
11. Hui Y, Qian J, Guo Y, et al. Efficacy analysis of three-year subcutaneous SQ-standardized specific immunotherapy in house dust mite-allergic children with asthma. Exp Ther Med 2014; 7:630-634.
12. Ye Z, Huang Y, Wang Y, et al. Effect of house dust mite vaccine on pulmonary function and inhaled corticosteroid doses in children with allergic asthma. J South Med Univ 2012; 32:1632-1635.
13. Baris S, Kiykim A, Ozen A, et al. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite. Allergy 2014; 69:246-253.
14. Nelson HS. Subcutaneous immunotherapy for optimal effectiveness. Immunol Allergy Clin North Am 2011; 31:211-226.